PMID- 34590042
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 2666-3643 (Electronic)
IS  - 2666-3643 (Linking)
VI  - 2
IP  - 7
DP  - 2021 Jul
TI  - Association Between the Early Discontinuation of Durvalumab and Poor Survival in 
      Patients With Stage III NSCLC.
PG  - 100197
LID - 10.1016/j.jtocrr.2021.100197 [doi]
LID - 100197
AB  - INTRODUCTION: Durvalumab after concurrent chemoradiation (cCRT) has been found to 
      improve outcomes of patients with unresected stage III NSCLC. However, the 
      survival impact of discontinuing durvalumab early owing to adverse events (AEs) 
      remains unknown. METHODS: Patients with stage III NSLCC treated with cCRT and 
      greater than or equal to one dose of durvalumab across a multisite cancer center 
      were evaluated. The median durvalumab treatment duration among patients who 
      discontinued owing to AEs (2.1 mo) defined two patient cohorts: early 
      discontinuation (<2.1 mo) and late discontinuation. Progression-free survival 
      (PFS) and overall survival were assessed. RESULTS: In total, 113 patients treated 
      with cCRT and a median of 8.5 months of durvalumab were assessed, of which 30 
      (26%) discontinued durvalumab owing to AEs after a median of 2.1 months of 
      treatment. Patients in the early- and late-discontinuation cohorts were treated 
      with a median of 0.9 and 4.3 months of durvalumab, respectively. The median PFS 
      among patients who did not discontinue durvalumab owing to AEs was 29.5 months. 
      Among patients that discontinued durvalumab owing to AEs, overall survival and 
      PFS were inferior in the early- versus late-discontinuation cohort (median PFS = 
      10.7 versus 32.9 mo, p < 0.001) and durvalumab treatment duration associated with 
      PFS on multivariate analysis (hazard ratio = 0.52 [95% confidence interval: 
      0.31-0.88], p = 0.014). CONCLUSIONS: We found that the duration of durvalumab 
      treatment among patients who discontinued therapy owing to AEs impacts survival. 
      However, patients treated with approximately 4 months of durvalumab maintained 
      outcomes as compared with patients who did not discontinue therapy owing to AEs. 
      Durvalumab rechallenge should be considered in patients with less than 2 months 
      of therapy.
CI  - (c) 2021 The Authors.
FAU - Shaverdian, Narek
AU  - Shaverdian N
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New 
      York, New York.
FAU - Offin, Michael
AU  - Offin M
AD  - Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering 
      Cancer Center, New York, New York.
FAU - Shepherd, Annemarie F
AU  - Shepherd AF
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New 
      York, New York.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AD  - Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering 
      Cancer Center, New York, New York.
FAU - Gomez, Daniel R
AU  - Gomez DR
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New 
      York, New York.
FAU - Chaft, Jamie E
AU  - Chaft JE
AD  - Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering 
      Cancer Center, New York, New York.
FAU - Rimner, Andreas
AU  - Rimner A
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New 
      York, New York.
LA  - eng
PT  - Journal Article
DEP - 20210610
PL  - United States
TA  - JTO Clin Res Rep
JT  - JTO clinical and research reports
JID - 101769967
PMC - PMC8474390
OTO - NOTNLM
OT  - Chemoradiation
OT  - Durvalumab
OT  - Pneumonitis
OT  - Stage III NSCLC
OT  - Toxicity
EDAT- 2021/10/01 06:00
MHDA- 2021/10/01 06:01
PMCR- 2021/06/10
CRDT- 2021/09/30 07:22
PHST- 2021/06/04 00:00 [received]
PHST- 2021/06/04 00:00 [accepted]
PHST- 2021/09/30 07:22 [entrez]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2021/10/01 06:01 [medline]
PHST- 2021/06/10 00:00 [pmc-release]
AID - S2666-3643(21)00056-4 [pii]
AID - 100197 [pii]
AID - 10.1016/j.jtocrr.2021.100197 [doi]
PST - epublish
SO  - JTO Clin Res Rep. 2021 Jun 10;2(7):100197. doi: 10.1016/j.jtocrr.2021.100197. 
      eCollection 2021 Jul.